Evocalcet is primarily used in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. It works by modulating the calcium-sensing receptors in the parathyroid glands, thereby reducing the secretion of parathyroid hormone (PTH). This helps in managing the levels of calcium and phosphorus in the blood, which are often imbalanced in such patients. By controlling PTH levels, Evocalcet aids in preventing complications like bone disorders and cardiovascular issues associated with chronic kidney disease. Its targeted action makes it a valuable therapeutic option for improving the quality of life in dialysis patients.